

Nucelion Therapeutics & VeGen Bio Partner on CAR-T Therapy

Prelims: Current events of national and international importance | Science & Technology

Why in news?

Bharat Biotech's arms, Nucelion and VeGen Bio, a Hyderabad-based precision oncology company, to partner for CAR-T therapy.

- **VL-2511** - A first-in-class dual-target autologous chimeric antigen (two cancer-related antigens) receptor (CAR)-T cell therapy that simultaneously targets BCMA and CD19 proteins.

***CAR-T (Chimeric Antigen Receptor T-cell) Therapy** - A personalised immunotherapy in which a patient's T-cells are genetically modified to recognise and destroy cancer cells.*

- **Collaboration** - Nucelion Therapeutics (a wholly owned subsidiary of Bharat Biotech) and VeGen Bio have announced a strategic partnership to develop and manufacture India's first dual BCMA/CD19 autologous CAR-T cell therapy, VL-2511, targeting multiple myeloma.
- **Collaboration's Objective** - To process optimisation, manufacturing yields, and operational efficiency to improve production economics, aiming to reduce manufacturing costs and improve access to advanced cell therapies in India.
- **Manufacturing Facility** - Production and technology transfer will take place at Nucelion's single-site GMP manufacturing facility in Hyderabad, designed to meet CDSCO, US FDA, and EMA regulatory standards.
- **Role of the partners** - VeGen Bio provides the therapeutic candidate and oncology expertise.
- Nucelion will handle technology transfer, clinical-stage manufacturing, and commercial-scale production at its GMP-certified Hyderabad facility.
- **Clinical and Commercial Goals** - The partnership will support Phase I and II clinical trials in India, with an overarching target for commercialisation by 2028.



References

1. [The Hindu | Bharat Biotech arm Nucelion, VeGen Bio to partner for CAR-T therapy](#)
2. [Business Line | Nucelion & VeGen Bio to partner for CAR-T therapy](#)